We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients...
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during...
-Enrolled patients allowed to continue on study- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.4 | -3.21027287319 | 12.46 | 12.62 | 12 | 4475 | 12.12847941 | CS |
4 | 0.46 | 3.96551724138 | 11.6 | 12.62 | 11.53 | 5689 | 11.87212171 | CS |
12 | 0.62 | 5.41958041958 | 11.44 | 12.62 | 11.44 | 10378 | 11.74470431 | CS |
26 | 0.31 | 2.63829787234 | 11.75 | 12.62 | 11.2 | 8061 | 11.63314749 | CS |
52 | 0.7 | 6.16197183099 | 11.36 | 12.62 | 10.65 | 6684 | 11.5700286 | CS |
156 | -0.26 | -2.11038961039 | 12.32 | 17.84 | 9.76 | 9104 | 12.32945487 | CS |
260 | -0.36 | -2.89855072464 | 12.42 | 17.84 | 5.58 | 8994 | 11.09256358 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions